Abstract: An autonomous rover including a frame having a first end and a second end longitudinally spaced from the first end and forming a payload bay, the payload bay being sized to support a pickface, a common active registration surface configured to engage the pickface, and a drive section connected to the common active registration surface, the drive section being configured to variably position the common active registration surface relative to at least one storage shelf of an automated storage and retrieval system to effect placement of the pickface on the storage shelf so that pickfaces are substantially continuously arranged along the at least one storage shelf with a predetermined storage spacing between the pickfaces.

Abstract: An electrical power system for a watercraft including a first electrical power plant configured to operate in a variable frequency mode to output variable frequency power to a first electrical network and a fixed frequency mode to output fixed frequency power to a second electrical network. There is a first electrical load including a first high temperature superconductor (HTS) motor connected to the first electrical network and a second electrical load connected to a second electrical network. A controller selectively connects the first electrical power plant to the first electrical network and operates the first electrical power plant in a variable frequency mode to output variable frequency power to power the first HTS motor and selectively connects the first electrical power plant to the second electrical network and operates the first electrical power plant in a fixed frequency mode to output fixed frequency power to power the second electrical load.

Abstract: An electrical power system for a watercraft including a first electrical power plant configured to operate in a variable frequency mode to output variable frequency power to a first electrical network and a fixed frequency mode to output fixed frequency power to a second electrical network. There is a first electrical load including a first high temperature superconductor (HTS) motor connected to the first electrical network and a second electrical load connected to a second electrical network. A controller selectively connects the first electrical power plant to the first electrical network and operates the first electrical power plant in a variable frequency mode to output variable frequency power to power the first HTS motor and selectively connects the first electrical power plant to the second electrical network and operates the first electrical power plant in a fixed frequency mode to output fixed frequency power to power the second electrical load.

Abstract: The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases including, e.g., cancer.

Abstract: The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases including, e.g., cancer.

Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Abstract: Presented herein are compounds that inhibit T-type Ca2+ channel activity in a cell when the cell membrane potential is about ?90 mV. Preferred compounds inhibit T-type Ca2+ channel activity with an IC50 of 10 ?M or less at a membrane potential of about ?90 mV. Preferred compounds show selectivity for inhibiting T-type Ca2+ channel activity at about ?90 mV, relative to inhibition of T-type Ca2+ channel activity at about ?30 mV to ?60 mV, of 10:1 or less. Also provided are methods for identifying compounds that inhibit T-type Ca2+ channel activity in a cell when the cell membrane potential is about ?90 mV, and compounds identified by such methods.

Abstract: A cable includes a plurality of bundles of insulated electrical conductors, each bundle having a first conductor, a second conductor, and a third conductor in a layered configuration. The first conductor of each bundle is connected in parallel to the first conductor of the remaining bundles, the second conductor of each bundle is connected in parallel to the second conductor of the remaining bundles, and the third conductor of each bundle is connected in parallel to the third electrical conductor of the remaining bundles. In addition, within each bundle, the first, second and third electrical conductors are configured so that a magnetic field generated in response to currents flowing within the bundle is zero as seen at a plane oriented transverse to an electrical conduction direction of the cable and located between the ends of the cable.

Abstract: A cable includes a plurality of bundles of insulated electrical conductors, each bundle having a first conductor, a second conductor, and a third conductor in a layered configuration. The first conductor of each bundle is connected in parallel to the first conductor of the remaining bundles, the second conductor of each bundle is connected in parallel to the second conductor of the remaining bundles, and the third conductor of each bundle is connected in parallel to the third electrical conductor of the remaining bundles. In addition, within each bundle, the first, second and third electrical conductors are configured so that a magnetic field generated in response to currents flowing within the bundle is zero as seen at a plane oriented transverse to an electrical conduction direction of the cable and located between the ends of the cable.

Abstract: A stator assembly for use in a superconducting generator operated at frequencies up to 10 Hz is disclosed. The stator assembly includes a ferromagnetic stator winding support having a plurality of teeth defining slots, the slots configured to receive and support stator windings. The stator winding support is formed so that the ratio of the sum of the widths of the slots to the sum of the widths of the teeth and slots is in the range of 0.65 to 0.90.

Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Abstract: A stator assembly for use in a superconducting generator operated at frequencies up to 10 Hz is disclosed. The stator assembly includes a ferromagnetic stator winding support having a plurality of teeth defining slots, the slots configured to receive and support stator windings. The stator winding support is formed so that the ratio of the sum of the widths of the slots to the sum of the widths of the teeth and slots is in the range of 0.65 to 0.90.

Abstract: A stator assembly for use in a superconducting generator operated at frequencies up to 10 Hz is disclosed. The stator assembly includes a ferromagnetic stator winding support having a plurality of teeth defining slots, the slots configured to receive and support stator windings. The stator winding support is formed so that the ratio of the sum of the widths of the slots to the sum of the widths of the teeth and slots is in the range of 0.65 to 0.90.

Abstract: Compositions for oral administration of compounds having A2A adenosine receptor antagonist activity are provided. These compositions are useful for treatment of inflammatory conditions.

Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.

Abstract: The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure: wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl or —NH(CO)—; R3 is H, C1-C4 alkyl, (C1-C4 alkyl)OH or (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is hydroxy, phosphonate, or wherein X and R12 is O or S; or a pharmaceutically acceptable salt or tautomer thereof.

Abstract: The present invention provides compositions for oral administration of compounds having A2A adenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.

Abstract: The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and; R2 is selected from the group consisting of H, C1-C4 alkyl, (C1-C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.

Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.